Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis

Published:2022-08 Issue: Volume:109 Page:108790
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Li Zi-Chun,Sun Yu-Ting,Lai Ming-Yu,Zhou Yi-Xin,Qiu Miao-Zhen

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference38 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J. Clin.,2022

2. Esophageal carcinoma;Ingelfinger;N Engl. J. Med.,2014

3. Clinical and Prognostic Features of Patients With Esophageal Cancer and Multiple Primary Cancers: A Retrospective Single-institution Study;Baba;Ann. Surg.,2018

4. The immune landscape of esophageal cancer;Huang;Cancer Commun. (Lond).,2019

5. Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer;Liu;Am. J. Cancer Res.,2016

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions;Expert Review of Clinical Immunology;2024-06-17

2. Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations;Cancer Treatment Reviews;2024-06

3. The Neoadjuvant Administration of PD-1 Inhibitor plus Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous-Cell Carcinoma;Journal of Clinical Pharmacy and Therapeutics;2024-04-12

4. From pixels to patient care: deep learning-enabled pathomics signature offers precise outcome predictions for immunotherapy in esophageal squamous cell cancer;Journal of Translational Medicine;2024-02-22

5. Comparison of the Efficacy and Safety of Perioperative Immunochemotherapeutic Strategies for Resectable Non-small Cell Lung Cancer: a Systematic Review and Network Meta-analysis;Clinical Oncology;2024-02